The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2023 | Challenges in treating patients with triple-class refractory multiple myeloma
Enrique Ocio, MD, PhD, Marqués de Valdecilla University Hospital, Santander, Spain, discusses major challenges in treating patients with triple-class refractory multiple myeloma, highlighting the need for novel agents and the importance of improving access to these. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
